

Enrofloxacin

Catalog No: tcsc2699



Available Sizes

Size: 5g

Size: 10g



Specifications

CAS No:

93106-60-6

Formula:

$C_{19}H_{22}FN_3O_3$

Pathway:

Anti-infection

Target:

Bacterial

Purity / Grade:

>98%

Solubility:

DMSO : 9.5 mg/mL (26.43 mM; Need ultrasonic and warming)

Alternative Names:

BAY-Vp2674;PD160788

Observed Molecular Weight:

359.39


Product Description

Enrofloxacin is an effective antibiotic with an MIC₉₀ of 0.312 µg/mL for *Mycoplasma bovis*.

IC50 & Target: MIC90: 0.312 µg/mL (*Mycoplasma bovis*)^[1]

In Vitro: *Mycoplasma bovis* is a worldwide pathogen, causative agent of pneumonia, mastitis, arthritis, and a variety of other symptoms in cattle. The antibiotic susceptibility profiles of the Hungarian strains are consistent within the tested group of fluoroquinolones. Three isolates (MYC44, MYC45 and MYC46) have high MIC values (≥ 10 µg/mL) to Enrofloxacin, while the rest of the strains are inhibited by Enrofloxacin with MICs ≤ 0.312 or 0.625 µg/mL^[1].

In Vivo: Mice (n=80) undergo transient middle cerebral artery occlusion (MCAo) with reperfusion after 60 minutes. After MCAo, animals are randomly assigned to receive either a daily preventive medication (n=26, Enrofloxacin) starting at the day of MCAo or a therapeutic medication (n=25; Enrofloxacin) after diagnosis of lung infection. Standard treatment started immediately after the appearance of clinical signs (general health score >6) usually between day 4 and 6 after stroke. Both, preventive and standard antibiotic treatment using Enrofloxacin improve survival in a similar way compared with placebo treatment^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!